openPR Logo
Press release

Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technology

12-03-2008 07:27 PM CET | Health & Medicine

Press release from: Protagen AG

/ PR Agency: Dr. Holger Bengs Biotech Consulting
Dortmund, Germany and New Jersey, USA, December 3, 2008. Protagen AG announces the closing of a cooperation contract with Bayer HealthCare AG, Leverkusen, Germany, about the evaluation of the UNIarray® technology for discovery of novel biomarkers in atrial fibrillation.

Bayer HealthCare is currently investigating atrial fibrillation after heart surgery in a clinical study. A certain number of patients develop this type of cardiac symptoms after surgery. Currently, it is not possible to predict the patients at risk of developing atrial fibrillation. Aim of the proof-of-principle study is to evaluate the UNIarray® technology for discovery of novel biomarkers for patient stratification and predictive diagnosis of atrial fibrillation.

UNIarray® of Protagen is a proprietary technology platform to develop novel diagnostics based on indication-specific autoantibody patterns in blood samples from patients. These autoantibody patterns are not only present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication-specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification for clinical studies. Protagen presently is focused on research at novel diagnostics for Prostate Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Morbus Parkinson, and Alzheimer´s Disease.

About Protagen AG
Protagen AG (www.protagen.de) is a leading provider of products, services and software solutions for protein research with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented platform for development and use of protein expression libraries, and UNIchip®, a versatile and highly efficient family of products for the development of antibodies, as well as UNIarray®, unique technology base for the development of new diagnostics.

About Bayer HealthCare AG
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.
Find more information at www.bayerhealthcare.com.

Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technology here

News-ID: 61438 • Views: 1048

More Releases from Protagen AG

Protagen and Charles River form strategic partnership
Dortmund, Germany, October 28, 2011. Protagen AG, Dortmund, a GMP-certified specialist in the characterization of protein drugs and Charles River Laboratories International, Inc., one of the world leading companies in high-quality research models and preclinical and clinical support services, are pleased to announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range
Protagen and OncoTyrol form strategic alliance to validate the UNIarray® techno …
Dortmund, Germany and New Jersey, USA, June 10, 2009. Protagen AG and the Medical University Innsbruck, Department of Urology, have recently identified autoantigen candidates present in serum of patients with prostate cancer using the proprietary UNIArray® technology platform. In Europe, prostate cancer is the second most frequent lethal malignancy in men. Yearly about 40,000 men die of prostate cancer in the European Union. Current standard of screening for prostate
Protagen meets with FDA
Dortmund, Germany and New Jersey, USA, February 19, 2009. Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces that it participated in two meetings with FDA personnel during the week of January 26, 2009. The meetings were intended to provide a detailed introduction to the company’s UNIarray® technology position and its potential use in the development of novel diagnostics for multiple sclerosis
Winner Consortium “NeuroAllianz” in the BioPharma Competition counts on UNIa …
Dortmund, Germany and New Jersey, USA, October 9, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips has won the BMBF’s BioPharma competition jointly with consortium “NeuroAllianz”. The twelve project partners will develop therapeutic as well as diagnostic approaches in the field of neurodegenerative diseases from bench to market under the direction of Professor Christa E. Mueller and Professor Alexander Pfeifer. Protagen

All 5 Releases


More Releases for Bayer

Drug Delivery Market 2018 | Johnson, Bayer
Report Summary The Global Drug Delivery Market Size is primarily driven by the increasing demand for technological advanced products that are used for drug delivery, and increased number of chronic diseases in the increasing number of geriatric population. Drug delivery is referred as drug administration in the human body through injections or various other devices. Drug delivery devices are used to inject the therapeutic substances in the body with the help of
Bayer Crop Sciences Ltd
Bayer Crop Sciences Ltd Bayer Crop Sciences Ltd- Company Profile & Financial Analysis” contains in depth information and data about the company and its operations. You will find information on the business structure, areas of operation, products and services offered by the company. It also comprises SWOT analysis, key ratios, historical financial data and insider’s view on financial stability and industrial ranking with financial forecasts for two- year period. This report is
Permethrin Market 2017 - Bayer, Heranba, Tagros, Meghmani
Apex Research, recently published a detailed market research study focused on the "Permethrin Market" across the global, regional and country level. The report provides 360° analysis of "Permethrin Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Permethrin industry, and estimates the future trend of Permethrin market on the basis of this
Global Spirotetramat Market 2017 : Bayer CropScience
Top Manufacture Analysis Of Spirotetramat Market 2017 Includes Market outline, section by Application, Market by Region and Production, Revenue (Value), worth Trend by kind. The Markets And analysis study delivers necessary information and realistic data of the globe Spirotetramat market. The report presents a deep study of the market growth factors and drivers. In-depth analysis of the Spirotetramat Market limitations and thus the opportunities modify the user to create the
Automotive Plastics Market 2017- AkzoNobel, BASF, Bayer
Marketreports.biz, recently published a detailed market research study focused on the "Automotive Plastics Market" across the global, regional and country level. The report provides 360° analysis of "Automotive Plastics Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Automotive Plastics industry, and estimates the future trend of Automotive Plastics market on
Global Pharmerging Market Research Report 2017: Bayer
This report studies Pharmerging in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering AstraZeneca GlaxoSmithKline Pfizer Sanofi Novartis Abbott Laboratories Shire Bayer Biogen F. Hoffmann-La Roche Johnson & Johnson Mitsubishi Tanabe Pharma Novo Nordisk Sun Pharmaceutical Takeda Pharma Teva Pharmaceutical Industries To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=973660&type=E Market Segment by Regions, this report splits Global into several key Regions, with production,